摘要
目的:系统评价补肾活血中药对比塞来昔布治疗膝骨性关节炎的疗效与安全性,为临床提供循证参考。方法:计算机检索中国期刊全文数据库、中国生物医学文献数据库、中文科技期刊数据库、万方数据库、Medline、Pub Med、Cochrane图书馆、中国博士学位论文全文数据库、中国优秀硕士学位论文全文数据库,收集补肾活血中药(试验组)对比塞来昔布(对照组)治疗膝骨性关节炎的随机对照试验(RCT),提取资料并进行文献质量评价后,采用Rev Man 5.3和Stata 12.0统计软件对纳入研究的结果进行Meta分析。结果:共纳入15项RCT,共1 129例患者。Meta分析结果显示,试验组患者总有效率[RR=1.09,95%CI(1.04,1.14),P<0.001]、视觉疼痛模拟(VAS)评分[MD=-0.49,95%CI(-0.94,-0.03),P<0.05]显著高于对照组,差异均有统计学意义;两组患者膝关节功能评分[关节炎患者疼痛指数(Lequesne):MD=0.24,95%CI(-1.20,1.68),P>0.05;Lysholm膝关节评分(Lysholm):MD=2.32,95%CI(-1.95,6.58),P>0.05;西安大略麦马斯特大学骨性关节炎可视化量表指数(WOMAC):MD=-2.87,95%CI(-6.38,0.64),P>0.05]和不良反应发生率[RR=0.49,95%CI(0.22,1.09),P=0.08]比较差异无统计学意义。结论:补肾活血中药治疗膝骨性关节炎的疗效和止痛效果均优于塞来昔布,而在改善患者的膝关节功能和安全性方面与塞来昔布相当。
OBJECTIVE： To systematically review the efficacy and safety of Bushen huoxue herb and celecoxib in the treat- ment of knee osteoarthritis, and provide evidence-based reference for clinical treatment. METHODS： Retrieved from CNKI, CBM, VIP and Wanfang Database, Medline, PubMed and Cochrane Library, randomized controlled trials （RCT） about Bushen huoxue herb （test group） and celecoxib（control group） in the treatment of knee osteoarthritis were collected. Meta-analysis was per- formed by using Rev Man 5.3 software after data extraction and quality evaluation. RESULTS： Totally 15 RCTs were included, in- volving 1 129 patients. Results of Meta-analysis showed, the total effective rate [RR=1.09,95% CI（1.04,1.14）,P〈0.01] and visu- al ache （VAS） score [MD=-0.49,95%CI（-0.94,-0.03）, P〈0.05] in test group were significantly higher than control group, the differences were statistically significant; there was no significant difference in knee fimction score [Lequesne：MD=0.24,95 %C1 （-1.20, 1.68）,P〉0.05; Lysholm： MD=2.32,95%CI（-1.95,6.58）,P〉0.05; WOMAC- MD=-2.87,95%CI（-6.38, 0.64）, P〉0.05] and the incidence of adverse reactions in 2 groups[RR=0.49,95% CI（0.22, 1.09）,P=0.08]. CONCLUSIONS： Bushen huoxue herb shows better efficacy and analgesic effect than celecoxib in the treatment of knee osteoarthritis, and is similar to celecoxib in terms of improving knee function score and safety.
出处
《中国药房》
CAS
北大核心
2016年第27期3810-3814,共5页
China Pharmacy
基金
广东省自然科学基金资助项目(No.2014A030310242)
